SDI FINAL EVALUATION FORM 1.1

PART 1:

Journal Name:	International Journal of Medical and Pharmaceutical Case Reports
Manuscript Number:	**Ms_IJMPCR_127531**
Title of the Manuscript:	**A Rare Presentation of Duchenne Muscular Dystrophy: Cardiac and Neurological Involvement**
Type of Article :	**Case report**

PART 2:

FINAL EVALUATOR'S comments on revised paper	**Authors' response to final evaluator's comments**
Regarding the drafting: - The bibliography citation must be noted before the point at the end of the sentence, not after - Keep in mind that certain phrases/information are repeated several times - In the Introduction chapter, where you quote bibliographic source 7, "It manifests as toe walking, climbing stairs, difficulty in running...", I assume you wanted to write "difficulty in climbing stairs" - Within the same paragraph mentioned above, it is medically correct to say "pseudohypertrophy of the calves" instead of "calf enlargement" - Also, it is not enough to mention only "Gower's sign", but to mention "Gower's sign positive/present" Regarding the medical information in the text: - In the Case report chapter, please rephrase the following sentence to better reflect the chronology of symptoms onset: Dysphagia to solids followed by vomiting (pseudo bulbar palsy) in the last 1 month, Dysphagia (solids >> liquids) in the past 3 months which increased in the last 10 days. Loss of weight, Loss of appetite for 1 year. - What exactly do you mean by "aggressiveness within appropriate laughter"? - Why do you say it is bulbar paralysis when the MRI is normal? - Why didn't you do a spirometry to evaluate the respiratory function? - There is a suspicion how a patient with DMD managed to live for 27 years without treatment for cardiac and respiratory impairment. Is it really DMD? - Genetic tests or muscle biopsy are required for positive diagnosis and differential diagnosis with Becker Muscular Dystrophy Regarding the treatment: - Ataluren can currently be used instead of Prednisone, as it has fewer adverse effects - Eteplirsen is also used - specific for the region of exon 51 of the DMD gene (through its binding to RNA, Eteplirsen causes exon skipping, which means that exon 51 is "skipped" during mRNA processing, which allows cells to produce a truncated but functional version of the dystrophin protein) or Drisapersen - with a	

similar mechanism of action to Eteplisren, with good results - Another therapeutic method currently used is CRISPR therapy, as gene editing therapy for DMD - Currently there are researches for the administration of portions of dystrophin	

PART 3: Objective Evaluation:

Guideline	MARKS for this REVISED manuscript
Give OVERALL MARKS you want to give to this REVISED manuscript (Highest: 10 Lowest: 0) **Guideline:** Accept (8-10) Revision required: (4-8) Rejected: (0-4)	

Reviewer Details:

Name:	**Singer Cristina**
Department, University & Country	**University of Medicine and Pharmacy of Craiova, Romania**